Emergency department visits and hospitalisations (ED+H) during systemic therapy are undesirable for both patients and the health system. We undertook a systematic literature review and meta-analysis to evaluate the frequency of unplanned all-cause and treatment-related ED+H among adults receiving adjuvant or palliative-intent systemic therapy for all cancers. Randomised controlled trials (RCT) and observational studies (OS) reporting ED+H were identified from Medline and EMBASE from inception to June 2016. Quality was assessed using modified STROBE, CONSORT or PRISMA guidelines, depending on study type. A total of 112 OS (308,662 patients) and 26 RCTs (16,081 patients) met inclusion criteria. Most articles focused on palliative treatment (59%) delivered as first-line, in breast, lung and colorectal cancers.
| INTRODUC TI ON
The concept of value is gaining prominence in health care in recent years in both clinical and research settings (Gross & Emanuel, 2015) .
Recent frameworks for assessing value of cancer treatment rely on accurate data to consider the balance between components such as relative clinical benefit, toxicity and costs in systems of finite resources (Cherny et al., 2015; Schnipper et al., 2015) . For chemotherapy, much work has been done to evaluate the clinical benefit aspect of the equation. Less is known about the toxicity component, which has both quality of life and cost implications, as poor reporting of adverse events in clinical trials is common (Scharf & Colevas, 2006; Sivendran et al., 2014) . Deficiencies include arbitrary groupings of adverse outcomes, reporting only adverse events occurring above a certain frequency threshold, and lack of reporting of infrequent but serious adverse events.
Emerging studies suggest that treatment-related toxicity in patients undergoing systemic therapy for cancer is common, particularly in populations receiving treatment in the routine practice setting when compared to clinical trial populations (Cancer Care Ontario, 2014; Du, Osborne, & Goodwin, 2002; Enright et al., 2015; Hanna et al., 2005; Hassett, O'Malley, Pakes, Newhouse, & Earle, 2006; Hoff et al., 2001; Jang et al., 2012; Sederholm et al., 2005; Twelves et al., 2001) , frequently requiring emergency department (ED) visits and hospitalisations for management. This is not surprising, as clinical trials populations are generally younger, have better performance status and fewer abnormalities on routine blood tests than patients treated in routine practice (Harter et al., 2005; Micol et al., 2014; Mitchell et al., 2015; Mol, Koopman, Gils, Ottevanger, & Punt, 2013; Sorbye et al., 2009; Templeton et al., 2013 ) and therefore may be at lower risk of toxicity. However, the frequency and potential risk factors associated with experiencing an ED visit or hospitalisation during systemic therapy have not been systematically evaluated. Understanding patterns of ED use and hospitalisation during systemic therapy for cancer in both clinical trials and routine practice is important for patients, providers and health systems yet has not been systematically evaluated. Information about potential treatment complications allows accurate risk assessment and appropriate informed consent, with tailored patient monitoring and education regarding complications. Health systems can benefit from more precise prediction of the likely need for acute care resources and associated costs, enabling system planning and redesign (Woolf & Johnson, 2005) .
To evaluate unplanned ED visits and hospitalisations in adults receiving either adjuvant or palliative systemic therapy for any cancer, we undertook a systematic review and meta-analysis. Our primary objective was to estimate the frequency of ED+H in both clinical trial and routine practice settings. As a secondary objective, we were also interested in factors associated with ED+H.
| ME THODS

| Data sources
We undertook a systematic search of Medline and EMBASE from database inception to June 30, 2016 for papers reporting the frequency of ED visits and hospitalisations in patients with cancer (both haematologic malignancies and solid organ tumours) of any stage undergoing systemic therapy. The search strategy is included in Supporting Information Appendix S1. Citations were imported into an electronic database (Endnote X7, Thomson Reuters, New York, NY, USA). The study was exempt from REB approval.
| Study selection
All identified citations were screened for potential eligibility based on the abstract by two reviewers (RP and MP). If study eligibility was unclear, a decision was made by consensus with a third reviewer (MK). A conservative threshold for second review was used meaning that any questions regarding study eligibility were discussed.
The population of interest was patients receiving systemic therapy in the outpatient setting. Studies in children, case reports, letters, editorials, review articles, abstract-only publications and those focusing on surgery and/or radiotherapy treatments were excluded.
| Data abstraction
A study-specific abstraction form was used to extract data from eligible papers by one investigator (RP). The number of patients experiencing an unplanned ED visit and/or being hospitalised, as well as repeated ED visits and hospitalisations, cause of ED visit and/or hospitalisation (treatment-related, all-cause), length of stay in hospital, with which cycle of therapy ED or hospitalisation occurred, and use of granulocyte colony-stimulating factors (G-CSF) were abstracted.
Visits were considered to be "treatment-related" if explicitly stated as such in the article. We also abstracted factors associated with ED visits and hospitalisations in either univariable or multivariable analyses when reported. To evaluate reliability of the data abstraction process, a second reviewer (AZ) extracted data from 12 randomly selected manuscripts in the cohort (approximately 10% of the total).
There were no discrepancies between reviewers.
| Assessment of study quality
Study quality metrics were collected for a subset of 74 papers (approximately 50%). Observational studies were assessed with a 26-point checklist adapted from the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (Vandenbroucke et al., 2007) as used in a previous study (Lee, Cheung, Atkinson, & Krzyzanowska, 2011) while quality of RCTs was assessed using the Consolidated Standards of Reporting Trials (CONSORT; Schulz, Altman, & Moher, 2010) checklist, of 34 (instead of 37; three items did not apply to any study so were removed from the total). A meta-analysis was evaluated using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (Liberati et al., 2009) , out of 27. Each paper was graded as follows: 1 if item was fully present, 0.5 for item partially present or 0 for item absent. Quality assessment was undertaken by one reviewer (RP).
| Statistical considerations
For studies with multiple treatment arms, the hospitalisation rates for each treatment arm were pooled in our analyses to give an overall rate per analysis. Studies with separate, parallel analyses were treated separately in the analysis. Summary statistics were used to describe the results. For categorical variables, the count was used if available or was obtained from the proportion and total sample size provided in the article. For continuous variables, the reported mean, sample size and variance (if reported) were used for estimation. If only median and range were reported, we used the Hozo, Djulbegovic, and Hozo (2005) method to estimate the mean and variance. Forest plots were created for each of the RCT and routine practice patient populations stratified by the type of hospitalisation data reported (all-cause vs. treatment-related). If a study reported both all-cause and treatment-related hospitalisations, they were included in both analyses. Groups were further stratified by tumour type, treatment intent, location and year of publication.
Aggregate data were used to evaluate the association of hospitalisation with potential covariates of interest using the chi-square test. Odds ratios (OR) were reported for covariates with two or more levels. Sample size divided by the variance was used as a weight to obtain summary statistics of the continuous covariates of interest for each of the RCT and routine practice patient populations.
Results were considered significant if p < 0.05. Multivariable results for hospitalisation risk factors are presented in cases where both univariable and multivariable analyses were reported by a study. All studies are analysed together as the numbers are too small to split the data according to type of analysis performed. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA) and R version 3.0 (The R Foundation for Statistical Computing, Vienna, Austria, 2013).
| RE SULTS
| Description of studies
The search strategy identified 27,198 citations pertaining to hos- Approximately 85% of papers examined cytotoxic chemotherapy; 8% evaluated targeted therapy, including tyrosine kinase inhibitors, mTOR inhibitors, angiogenesis inhibitors, monoclonal antibodies and DNA damaging agents while 7% examined both chemotherapy and targeted therapy, mainly with combinations incorporating bevacizumab or rituximab. We did not identify any papers evaluating ED+H use during hormonal therapy. G-CSF use was reported in 59% of papers with the majority indicating that prophylactic G-CSF was not used.
| Quality of reporting
Duration of exposure to systemic therapy was poorly reported across most articles with only 39 papers defining the number of treatment cycles received by patients (median 5, range 1-13) and 15 papers reporting the total duration of therapy (median 2.7 months, range 2.3-24.2 months). The timing of acute care events relative to starting systemic therapy and the time period over which these events were monitored for (i.e. the "at-risk" period) were poorly reported with 96 papers reporting outcome events "during chemotherapy" without specifying a time frame and only 22 articles providing a specific definition. Additional reporting gaps were evident for outcome assessments, especially how ED visits or hospitalisations were identified and how cause was ascertained.
In the subset of 74 papers (58 observational studies, 16 RCTs) assessed for quality of reporting, the quality of the observational studies according to the modified STROBE checklist was poor, with a median score of 18 of a possible 26 . Checklist items including rationale for the study, the number of events for each specified outcome and summary of key findings with reference to the study objectives were reported well in observational studies, whereas addressing sources of bias, explaining how missing data and lost to follow-up were handled and identification of the source of funding for the study was handled poorly.
The median CONSORT score for the RCTs was 21.5 of 34 (IQ range 18-23). Areas that were reported well-included explanation of the scientific rationale, and reporting of eligibility criteria, intervention details and statistical methods. Lack of sufficiently detailed explanation of the methods used by investigators to randomise participants was a key gap. The meta-analysis scored poorly on PRISMA guidelines.
| Hospitalisations
The majority of papers reported the frequency of unplanned hospitalisations during systemic therapy (99%). For both treatment-related ( Figure 1a ) and all-cause hospitalisations (Figure 1b) , a greater proportion of patients treated in routine practice were hospitalised at least once during systemic therapy compared to patients treated in trials (29% vs. 16%, OR 2.2, 95% CI 2.1-2.3, p < 0.0001 for treatment-related; and 42% vs. 28%, OR 1.9, 95% CI 1.8-2, p < 0.0001 for all-cause). The differences between patients treated in routine practice and RCTs were more pronounced for certain clinical scenarios where data were available from both kinds of studies. all finding that hospitalisations were most frequent with cycle one of treatment. Duration of hospitalisation was reported in 26 articles; length of stay ranged from 0 to 228 days with a median duration of 6.5 days. Nineteen articles examined repeated hospitalisations during systemic therapy, finding rates between 1% and 75%.
Seventeen of the 138 articles also included a patient population diagnosed with the same cancer who did not receive systemic therapy.
Of these, 11 reported the proportion of patients who did not receive systemic therapy who were hospitalised. All were retrospective, nine were population-based and used cancer registries linked to administrative databases or another database as their data source while two were multi-institution cohort studies. A variety of tumour types were examined including breast, colorectal, ovarian, lung, pancreas and any cancers, split evenly between palliative, adjuvant and any intent settings. These studies found that receipt of systemic therapy was associated with increased odds of hospitalisation (OR 1.29, 95% CI 0.5-2).
| ED visits
All 20 articles reporting unplanned ED visits were observational studies ( Figure 1b) . Seven used cancer registries, five used other databases (one used a RCT cohort matched with an administrative database, four used administrative databases), and there were six single institution and two multi-institution experiences. These articles addressed a range of tumour types and treatment intent including breast (any intent and adjuvant), gynaecological/genitourinary (adjuvant and palliative), gastrointestinal (adjuvant and palliative), lung (palliative), brain (palliative) and any cancer (adjuvant and any intent). The proportion of patients who had ED visits ranged from 6% to 83%. Two papers also reported ED visits in cancer patients who did not receive chemotherapy. Both found that patients receiving chemotherapy were more likely to visit ED (Hassett et al., 2006; Sanoff et al., 2012) . Age, comorbidities and regimen were the most frequently evaluated Characteristic All studies, n = 138 (n, %) Observational studies, n = 112 (n, %) RCTs, n = 26 (n, %) (84) 94 (82) 24 (92) Targeted therapy 11 (8) 11 (10) Chemo and targeted therapy 10 (7) 9 (8) 2 (8) Line of treatment Adjuvant/curative 36 (26) 32 (28) 4 (16) Palliative 82 (59) 60 (53) 22 (85) 1st line 43 (52) 26 (43) 17 (77) 2nd line 14 (17) 11 (18) 3 (14) Any 22 (27) 21 (35) 1 (5) Any intent 22 (16) 22 (19) Use of prophylactic G-CSF Yes 15 (11) 14 (12) 1 (4) No 67 (48) 46 (40) 21 (81) Not reported 58 (41) 54 (47) 4 (16) Notes. Chemo: chemotherapy; ED: emergency department; G-CSF: granulocyte colony-stimulating factor; HCC: hepatocellular carcinoma; RCT: randomised controlled trial. a One paper undertook three analyses using different databases. These were considered separately in our analyses. 
| Factors associated with acute care visits
TA B L E 1 (Continued)
F
| D ISCUSS I ON
To evaluate the magnitude of acute care use in adult patients with cancer undergoing treatment with systemic therapy, we examined the overall frequency of hospitalisations and ED visits using data from multiple published sources. We found that a substantial proportion of patients with cancer treated with systemic therapy especially those receiving care in routine care settings are hospitalised during treatment. The proportion of hospitalisations that were considered treatment-related was approximately half all-cause hospitalisations in studies that reported both parameters. Furthermore, we have examined specific patient populations (routine care, RCT, adjuvant, palliative) looking for drivers of the patterns seen as these can then be used as the starting point for targeted interventions. These findings have significant implications for patients, providers and health systems from cost, resource utilisation, supportive care and clinical demand perspectives. The rate of treatment-related hospitalisations may be a good estimate of toxicity associated with systemic therapy, F I G U R E 2 Factors associated with hospitalisation in observational studies and RCTs. Alb: albumin; Cr: creatinine; Hb: haemoglobin; AST: aspartate aminotransferase; WCC: white cell count; N/H: nursing home; SAE: severe adverse event; Gl: gastrointestinal; GCSF: granulocyte colony stimulating factor; RCT: randomized controlled trial; CXT: chemotherapy; MMSE: Mini-mental state examination.
which can inform discussions on the value of a particular regimen and guide proactive support during treatment. Collation of the available data has also allowed for identification of gaps in reported data and study quality, allowing us to make recommendations about how these issues can be addressed in future.
Previous research suggests that patients treated in routine practice may not derive the same benefit from treatment as clinical trial participants treated with similar regimens (Field et al., 2013; Sekine, Takada, Nokihara, Yamamoto, & Tamura, 2006; Sorbye et al., 2009; Templeton et al., 2013) . Our findings suggest that patients treated in routine practice may also experience more toxicity. This is not surprising as patients treated in routine practice may not be comparable to patients treated in clinical trials who are generally younger, have better performance status and fewer abnormalities on routine blood tests (Harter et al., 2005; Micol et al., 2014; Mitchell et al., 2015; Mol et al., 2013; Sorbye et al., 2009; Templeton et al., 2013) .
High rates of emergency department visits in patients with cancer during treatment have important ramifications for both patient care and resource use. We need to understand the characteristics of these visits more fully, but they are rarely reported in the litera- A number of methodological shortcomings were observed in the articles we reviewed. These included poor definition of the "at-risk" period for acute care visits, and lack of details regarding ascertainment of acute care visits and attribution of causality. To address these gaps, we include some suggestions for the reporting of acute care events (ED visits and hospitalisations) during systemic therapy in identification and ascertainment of these events were carried out was less than ideal. This may have led to overestimation of frequency of hospitalisation during receipt of systemic therapy especially in the palliative setting if the "at-risk" period extended beyond therapy completion.
In addition, we do not know whether publication bias exists for toxicity reporting. It is well recognised that publication bias exists regarding efficacy reporting (Dickersin, Chan, Chalmersx, Sacks, & Smith, 1987; Dwan et al., 2008; Krzyzanowska, Pintilie, & Tannock, 2003; Tam, Tannock, Massey, Rauw, & Krzyzanowska, 2011) . If publication bias in reporting toxicity outcomes exists, leading to underpublishing of studies with high rates of hospitalisations, the effect would be to decrease the difference we have found between the observational and clinical trial populations. We are unable to determine from our review why there are differences in hospitalisation between different patient populations. While we collected data on factors associated with hospitalisations in the few articles reporting these parameters, we were unable to draw concrete conclusions due to significant variation in which factors were examined and how these factors were defined which lead to small sample sizes. Further research into factors associated with hospitalisations is needed as they represent potential targets for interventions aimed at reducing hospitalisations; this should be done using standardised methods with clearly defined variables to allow more meaningful conclusions to be drawn. Understanding factors associated with acute care visits may facilitate identification of strategies for reducing hospitalisations and ED visits during treatment.
The increasing demands and rising costs (Porter, 2010; Schnipper et al., 2015) faced by health systems dictate that we find ways to increase quality of care while reducing costs. Decreasing acute care utilisation could realise both of these objectives. Patient-centred medical homes for oncology patients represent an emerging model of care
showing promising results in decreasing ED visits and hospitalisations with resultant cost savings (Sprandio, 2010 (Sprandio, , 2012 Waters et al., 2015) .
Proactive symptom monitoring at and between clinic visits is another promising strategy (Basch et al., 2016 ).
In conclusion, we have found that hospitalisations and ED visits 
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